This is a preview of subscription content, log in via an institution to check access.
Reference
Li A, et al. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. Cancer : 30 Jan 2020. Available from: URL: http://doi.org/10.1002/cncr.32724
Rights and permissions
About this article
Cite this article
Oral anticoagulants cost effective for thrombosis prevention in cancer. PharmacoEcon Outcomes News 847, 23 (2020). https://doi.org/10.1007/s40274-020-6599-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6599-6